William Blair currently has a $58.00 price target on the stock. The analysts wrote, "We note the scarcity in the midcap pharmaceuticals sector for diversified companies such as Akorn, and it is difficult to ignore the significant consolidation underway within the sectorWith Akorn being one of the only companies still paying a full tax rate, we believe significant weakness would make the company a target for acquisition."